Induction chemotherapy with albumin-bound paclitaxel plus lobaplatin followed by concurrent radiochemotherapy for locally advanced esophageal cancer

Table 1 Baseline characteristics of patients

Feature	n (%)
Gender
Male	29 (100)
Female	0 (0)
Age [yr; median (range)]	62 (56, 65)
Clinical stage
III	15 (51.7)
IV	14 (48.3)
Tumor location
Upper thoracic esophagus	6 (20.7)
Upper part of middle thoracic esophagus	3 (10.3)
Middle thoracic esophagus	6 (20.7)
Lower part of middle thoracic esophagus	8 (27.6)
Lower thoracic esophagus	6 (20.7)

Table 2 Short-term efficacy, n (%)

	After induction chemotherapy	After induction chemotherapy + concurrent radiochemotherapy
ORR	16 (61.54)	20 (76.92)
PR	16 (61.54)	20 (76.92)
SD	7 (26.92)	3 (11.54)
PD	3 (11.54)	3 (11.54)

ORR: Objective response rate; PR: Partial response; SD: Stable disease; PD: Progressive disease.

Table 3 Adverse events (n = 29)

	Grade 1 or 2 (%)	Grade 3 (%)
Hematologic toxicities
Anemia	3.85	0
Leukopenia	69.23	10.35
Neutropenia	61.54	6.9
Thrombocytopenia	15.4	0
Non-hematologic toxicities
Decreased appetite	13.79	0
Fatigue	13.79	0
Radiation-induced esophagitis	34.48	13.79
Decreased body weight	3.45	0
Abnormal liver function	3.45	0